Bicocca Open Archive

Logo unimib boa
BIDOLI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.707
AS - Asia 6.044
EU - Europa 3.849
SA - Sud America 949
AF - Africa 135
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 3
Totale 21.699
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.832
SG - Singapore 2.350
HK - Hong Kong 1.151
CN - Cina 1.088
RU - Federazione Russa 820
CA - Canada 805
BR - Brasile 701
IE - Irlanda 614
IT - Italia 604
VN - Vietnam 529
DE - Germania 491
SE - Svezia 461
IN - India 198
GB - Regno Unito 179
FR - Francia 177
UA - Ucraina 122
BD - Bangladesh 119
FI - Finlandia 95
AR - Argentina 93
TR - Turchia 76
AT - Austria 75
IQ - Iraq 74
ID - Indonesia 73
PK - Pakistan 60
JP - Giappone 58
SA - Arabia Saudita 45
MX - Messico 42
PH - Filippine 41
DK - Danimarca 39
ZA - Sudafrica 39
CO - Colombia 36
ES - Italia 35
KR - Corea 34
NL - Olanda 33
VE - Venezuela 33
EC - Ecuador 30
PL - Polonia 25
UZ - Uzbekistan 25
BE - Belgio 19
JO - Giordania 17
CL - Cile 14
PY - Paraguay 14
KE - Kenya 12
MA - Marocco 12
UY - Uruguay 12
AE - Emirati Arabi Uniti 11
NP - Nepal 11
PE - Perù 11
AU - Australia 10
EG - Egitto 10
DZ - Algeria 8
ET - Etiopia 8
IR - Iran 8
JM - Giamaica 8
KZ - Kazakistan 8
TN - Tunisia 8
LB - Libano 7
TH - Thailandia 7
AZ - Azerbaigian 6
MY - Malesia 6
RO - Romania 6
SN - Senegal 6
AL - Albania 5
AO - Angola 5
BA - Bosnia-Erzegovina 5
BO - Bolivia 5
IL - Israele 5
MU - Mauritius 5
PS - Palestinian Territory 5
RS - Serbia 5
AM - Armenia 4
BG - Bulgaria 4
CR - Costa Rica 4
DO - Repubblica Dominicana 4
KG - Kirghizistan 4
LT - Lituania 4
MN - Mongolia 4
NG - Nigeria 4
PA - Panama 4
TW - Taiwan 4
BY - Bielorussia 3
CI - Costa d'Avorio 3
GA - Gabon 3
GR - Grecia 3
LV - Lettonia 3
NO - Norvegia 3
OM - Oman 3
PT - Portogallo 3
BH - Bahrain 2
CG - Congo 2
CZ - Repubblica Ceca 2
EU - Europa 2
GE - Georgia 2
GT - Guatemala 2
HN - Honduras 2
HU - Ungheria 2
IS - Islanda 2
MD - Moldavia 2
MT - Malta 2
NZ - Nuova Zelanda 2
Totale 21.669
Salva come PNG Salva come JPEG
Città #
Singapore 1.333
Ann Arbor 1.331
Hong Kong 1.114
Ashburn 944
Fairfield 850
Toronto 718
San Jose 609
Dublin 606
Woodbridge 481
Wilmington 435
Seattle 389
Chandler 372
Houston 328
Cambridge 321
New York 308
Frankfurt am Main 296
Princeton 248
Beijing 221
Chicago 221
The Dalles 216
Jacksonville 167
Santa Clara 159
Ho Chi Minh City 156
Los Angeles 145
Shanghai 136
Hanoi 124
Altamura 122
Lauterbourg 119
Lawrence 118
Milan 116
Dallas 102
Council Bluffs 84
Moscow 78
San Diego 73
Helsinki 68
Dearborn 63
São Paulo 56
Jakarta 51
Vienna 51
Buffalo 46
Andover 44
London 40
Guangzhou 39
Boardman 37
Baghdad 34
Nanjing 33
Tokyo 33
Hefei 32
Rio de Janeiro 30
Salt Lake City 30
Munich 29
Orem 29
Hangzhou 28
Nuremberg 28
Haiphong 26
Pune 26
Turin 26
Dhaka 25
Ottawa 25
Rome 24
Washington 24
Columbus 23
Falls Church 23
Dong Ket 22
Lahore 22
Seoul 22
Da Nang 21
Riyadh 21
Tashkent 20
Chennai 19
San Francisco 19
Brussels 18
Norwalk 18
Atlanta 17
Johannesburg 17
Tianjin 17
Mumbai 16
Phoenix 16
Amman 15
Jinan 15
Amsterdam 14
Tampa 14
Warsaw 14
Boston 13
Brasília 13
Elk Grove Village 13
Hebei 13
Redmond 13
Zhengzhou 13
Brooklyn 12
Changsha 12
Guayaquil 12
Istanbul 12
Jeddah 12
Karachi 12
Lachine 12
Montreal 12
Torre Del Greco 12
Denver 11
Hải Dương 11
Totale 14.628
Salva come PNG Salva come JPEG
Nome #
Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study. 449
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 396
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 386
Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab 377
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 368
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 349
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS) 339
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings 322
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 311
"Why my parent is ill?" A specific, multidisciplinary intervention to enhance comunication to cancer patients' children 307
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma 307
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 300
Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue 294
C-arm cone-beam CT-guided transthoracic lung core needle biopsy as a standard diagnostic tool 292
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools 269
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 263
Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc©) in patients with chemotherapy-induced peripheral neuropathy 262
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial 248
When progressive dysphagia could be related to an “old friend” – a case report 240
Dorsal sural nerve conduction study in the assessment of oxaliplatin induced peripheral neuropathy 231
Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis 231
Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial 229
Liquid biopsy testing can improve selection of advanced non-small-cell lung cancer patients to rechallenge with gefitinib 226
Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective 221
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 218
Novel cytotoxic chemotherapies in small cell lung carcinoma 218
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 207
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population 200
Normalization of the light/dark rhythm of melatonin after prolonged subcutaneous administration of interleukin‐2 in advanced small cell lung cancer patients 198
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases 198
Molecular and immune biomarkers for cutaneous melanoma: Current status and future prospects 192
Anti PD-L1 antibody: is there a histologic-oriented efficacy? Focus on atezolizumab in squamous cell non-small cell lung cancer 191
Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab 191
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial 189
Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift 186
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 186
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations 185
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study 185
Focus on nivolumab in NSCLC 184
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer 184
Second-line erlotinib or intermittent erlotinib plus docetaxel in male ex-smokers with squamous NSCLC: The TALISMAN randomized trial 183
Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review 182
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) 181
Nutritional support in patients with cancer of the esophagus: impact on nutritional status, patient compliance to therapy, and survival 178
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial 177
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer 172
Malignant mesothelioma in subjects with Marfan's syndrome and Ehlers-Danlos syndrome: only an apparent association? 171
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study 168
Esophageal squamous cell carcinoma: MRI evaluation of mediastinum 165
Chronic effects of subcutaneous interleukin-2 therapy on soluble interleukin-2 receptors in advanced small cell lung cancer 163
Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors 162
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial 161
Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer 159
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial 159
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial 158
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study 157
Drugs ten years later: epirubicin 157
Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer 157
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study 157
Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study 156
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study 154
Pilot study with cisplatin, ifosfamide, and etoposide in advanced non-small-cell lung carcinoma 152
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial 151
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial 151
Pilot study with adriamycin and ifosfamide in small cell lung cancer 150
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 149
Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a phase II trial 149
FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer 148
Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer 148
Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review 148
Gene product immunophenotyping of neuroendocrine lung tumors. No linking evidence between carcinoids and small-cell lung carcinomas suggested by multivariate statistical analysis 147
Prognosis after nonradical resections for small cell lung carcinoma (SCLC) 146
Surgical resection in the treatment of stages I-II of small cell lung carcinoma (SCLC) 145
Antiemetic activity of metoclopramide versus alizapride during cancer chemotherapy 143
Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus 142
The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients 142
Oxaliplatin doublets in non-small cell lung cancer: A literature review 141
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer 141
EAGLES study: First-line bevacizumab in combination with chemotherapy in elderly patients with advanced, metastatic, non-squamous non-small cell lung cancer 141
A new race against lung cancer 140
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer 140
Targeted therapies and immunotherapy in non-small-cell lung cancer 139
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 139
A summary of the Milan experience with multimodality therapies in patients with small cell lung cancer: Attempts to improve long-term outcome 137
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer 137
Comparative in vitro sensitivity of human cholangiocarcinoma and colon adenocarcinoma cells to anticancer agents 137
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 136
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer? 135
Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: Analysis of 318 patients 134
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer 134
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) [Trattamento con Gefitinib nei pazienti anziani o con scarso performance status (PS), affetti da carcinoma polmonare non a piccole cellule (NSCLC)] 131
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial 131
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial 130
Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer 130
Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer 130
Isolated cardiac metastasis from squamous cell esophageal cancer 129
Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase I study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity 128
Induction chemotherapy with carboplatin/paclitaxel followed by surgery or standard radiotherapy and concurrent daily low-dose cisplatin for locally advanced non-small cell lung cancer (NSCLC) 127
Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythms of cortisol and beta-endorphin in advanced small cell lung cancer patients 126
Efficacy and safety of vinorelbine-capecitabine oral metronomic combinaton in elderly metastatc breast cancer patents: VICTOR-1 study 124
Totale 19.234
Salva come PNG Salva come JPEG
Categoria #
all - tutte 83.256
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 83.256
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021369 0 0 0 0 0 0 0 0 0 0 179 190
2021/20221.233 107 156 159 71 40 86 79 62 67 53 96 257
2022/20231.894 273 635 127 134 83 303 33 99 131 21 30 25
2023/20241.867 32 36 59 59 272 498 377 101 205 14 17 197
2024/20253.752 219 500 198 171 301 132 213 80 463 555 277 643
2025/20268.023 783 521 464 642 908 451 1.591 452 710 572 929 0
Totale 22.307